Drug Profile

CHO A04

Alternative Names: CHO-A04

Latest Information Update: 10 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Academia Sinica
Developer CHO Pharma
Class Antineoplastics; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; Cell death stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Solid tumours

Most Recent Events

03 Jul 2025 Cho Pharma plans a phase I/IIa trial for Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease) in Taiwan (IV) (NCT07049458)
28 Aug 2021 No recent reports of development identified for preclinical development in Cancer in Taiwan (Parenteral)
20 Jul 2017 Preclinical trials in Cancer in Taiwan (Parenteral) (CHO Pharma pipeline, July 2017)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com